Innovative path into China market – Key legal considerations in a drug licensing agreement.Are you ready?
Collaboration and licensing agreements are an indispensable business strategy for both pharmaceutical companies with commercial capabilities and biotech companies developing novel therapeutics. With collaboration agreements, efforts to develop, seek regulatory approval, manufacture, and market a product are conducted jointly at one or more stages along the drug development pipeline. When collaboration and licensing agreement disputes arise, the repercussions can be costly… what shall be considered at a licensing agreement?- Key legal considerations/elements of a licensing deal
- The unique issues for China related cross border deals
- Case study
Event details
|
DATE Wednesday April 15, 2020 VENUE Webex TIME Berlin time 13:00 – 14:00 (China time 7PM – 8PM) RSVP This is a FREE event This webinar is in English VIP tickets priority for Lingmed current clients Please RSVP by April 14, 2020 |
PRESENTERS Lingling Cao, CEO & Founder David Shen, IP lawyer, Allen Overy Guest speaker REGISTER +86 21 5386 3003, info@lingmed.net |
Agenda Berlin time @13:00 (China time 19:00)
| 13:00 - 13:10 | Linkedbio services & projects introductions | by LingLing Cao |
| 13:10 - 13:45 | Key legal considerations in a drug licensing agreement | by David Shen |
| 13:45 - 13:55 | Panel discussions | |
| 13:55 - 14:00 | Q&A |
Presenters
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |
 |
David Shen IP lawyer, Allen Overy Guest speaker David heads the IP practice in China. Native Chinese and an experienced U.S. patent lawyer, David has extensive experience in representing multinational companies in the protection, licensing, and enforcement of IP rights in China. David’s IP experience includes significant patent, trademark and branding experience with a particular focus on the life sciences sector. With a strong technical background, a deep understanding of the Chinese legal system, and a global view on IP protection, David offers unparalleled legal support to companies doing business in China. David was formerly the China General Counsel for a leading global multinational pharmaceutical company. “David provides technically savvy counsel of the utmost value, enforcing life sciences rights globally and negotiating complex licensing agreements.” IAM 1000, 2018 |